March 2023

Impact of NSAIDs on 8-year Cumulative Incidence of Major Cardiovascular Events in Patients with Ankylosing Spondylitis: A Nationwide Study

Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead072

MACEs were observed in patients newly receiving compensation from the Long-term Illness Scheme for AS. The objective of this study was to describe the incidence of MACEs in French patients newly benefiting from the French LTI for AS. The study also sought to evaluate the effect of various treatments on the risk of MACE occurrence.

Keywords:

Safety Profile of Upadacitinib over 15 000 Patient-years Across Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Atopic Dermatitis

RMD Open. 2023;9(1):e002735 doi: 10.1136/rmdopen-2022-002735

Integrated analysis of the safety profile of upadacitinib demonstrates that it was generally well-tolerated in RA, PsA, AS and AD, with no new safety risks identified, compared with previous reports.

Keywords:

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

Adv Ther. 2023;40(4):1867–1883 doi: 10.1007/s12325-023-02445-w

Analysis of pooled data from the baricitinib clinical development programmes finds a low incidence rate of MACE, myocardial infarction, lung cancer, VTE, and overall mortality in patients <65 years without risk factors.

Keywords:

Safety of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis as used in Clinical Practice: Results from the ARTIS Programme

Ann Rheum Dis. 2023;82(5):601–610 doi: 10.1136/ard-2022-223762

Nationwide register-based cohort study corroborates and extends previous evidence that the currently available biologic/targeted synthetic DMARDs have an acceptable and, on the whole, similar safety profile.

Keywords:

Malignancy Risk with Tofacitinib versus TNF Inhibitors in Rheumatoid Arthritis: Results from the Open-Label, Randomised Controlled Oral Surveillance Trial

Ann Rheum Dis. 2023;82(3):331–343 doi: 10.1136/ard-2022-222543

Results from the open-label, randomised controlled ORAL Surveillance trial find increased risk of malignancies with tofacitinib versus TNFi, highlighting the highest incidence in patients with a history of atherosclerotic cardiovascular disease or increasing cardiovascular risk.

Keywords:

February 2023

Efficacité clinique d'un inhibiteur alternatif du TNF et du sécukinumab chez les patients non-répondeurs primaires et secondaires à un inhibiteur antérieur du TNF dans la spondylarthrite ankylosante

Mod Rheumatol. 2023 doi: 10.1093/mr/roac005

This study demonstrated comparable drug retention between AS patients treated with alternative TNFi and secukinumab after failing to respond to prior TNFi therapy. The objective of this study was to compare the drug retention times and clinical efficacy of alternative TNFi and secukinumab in primary and secondary
non-responders with AS.

Keywords:

L'enthésite du tendon Achille à l'examen physique entraîne de moins bons résultats après 2 ans de suivi chez les patients atteints de spondylarthrite ankylosante du Registre REGISPONSER-AS

Arthritis Res Ther. doi: 10.1186/s13075-023-02988-x

The results highlighted the long-term impact of the presence of Achilles enthesitis on the burden of disease. The objectives of this study were to evaluate the impact of Achilles' tendon enthesitis found at baseline during physical examination on the outcome measures after 2 years of follow-up in patients with AS.

Keywords:

Efficacité et sécurité du bimekizumab dans la spondylarthrite axiale : Résultats de deux essais contrôlés randomisés de phase 3 menés en parallèle

Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595

Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.

Keywords:

L'effet du guselkumab sur l'inhibition de la progression radiographique chez les patients atteints de rhumatisme psoriasique actif : Protocole d'étude pour APEX, un essai de phase 3b, multicentrique, randomisé, en double aveugle, contrôlé par placebo

Trials. 2023 doi: 10.1186/s13063-022-06945-y

Guselkumab was approved for treating the signs and symptoms of active PsA following two Phase 3 global studies, DISCOVER-1 and DISCOVER-2. The Phase 3b APEX study has been designed to address the limitations of DISCOVER-2 and further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.

Keywords:

Zona chez les patients atteints d'arthrite inflammatoire ou de colite ulcéreuse traités par le tofacitinib, le baricitinib ou l'Upadacitinib: Revue systématique des essais cliniques et des études en monde réel

Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.

Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.

Keywords: